Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 490

MOTION for Summary Judgment That The Claims Of Patents-In-Suit Are Invalid For Double Patenting Over Amgen 016 Patent by F. Hoffmann-LaRoche LTD, Roche Diagnostics GmbH, Hoffmann LaRoche Inc..(Rizzo, Nicole)

Download PDF
Amgen Inc. v. F. Hoffmann-LaRoche LTD et al Doc. 490 Case 1:05-cv-12237-WGY Document 490 Filed 06/12/2007 Page 1 of 3 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS AMGEN INC., Plaintiff, vs. F. HOFFMANN-LA ROCHE LTD; ROCHE DIAGNOSTICS GmbH; and HOFFMANN-LA ROCHE INC. Defendants. ) ) ) ) ) ) ) ) ) ) ) ) ) CIVIL ACTION No.: 05-CV-12237WGY ORAL ARGUMENT REQUESTED DEFENDANTS' MOTION FOR SUMMARY JUDGMENT THAT THE CLAIMS OF PATENTS-IN-SUIT ARE INVALID FOR DOUBLE PATENTING OVER AMGEN `016 PATENT Defendants F. Hoffmann-La Roche Ltd, Roche Diagnostics GmbH, and Hoffmann-La Roche, Inc. (collectively "Roche") submit this motion for summary judgment that the claims of the patents-in-suit are all invalid for obviousness-type double patenting over claim 10 of Amgen's earlier-issued and now-expired U.S. Patent No. 4,667,016 ("the `016 patent"). Claim 10 of the `016 patent is directed to the harvesting of purified "recombinant erythropoietin from a mammalian cell culture supernatant fluid," and this recombinant erythropoietin is the product that is the subject of Amgen's patents-in-suit. Thus, the processes, proteins, compositions, and uses of rEPO in treatments described in the asserted claims are just a rewording or obvious variation of the process claims of the `016 patent. Indeed, past positions taken by Amgen and its experts--and adopted by the courts and the United States Patent and Trademark Office--underscore the invalidity of the claims-in-suit for obviousness-type double patenting over the `016 patent. Dockets.Justia.com Case 1:05-cv-12237-WGY Document 490 Filed 06/12/2007 Page 2 of 3 Thus, Roche respectfully asks this Court to grant its motion for summary judgment that the claims of the patents-in-suit are invalid for double patenting over claim 10 of the `016 patent. In support of this motion, Roche submits the accompanying memorandum of law, the Declarations of Dr. Edward Everett Harlow, Jr., Michael Sofocleous, and Kimberly J. Seluga, and a Rule 56.1 Statement of Undisputed Material Facts. CERTIFICATE PURSUANT TO LOCAL RULE 7.1 I certify that counsel for the parties have conferred in an attempt to resolve or narrow the issues presented by this motion and that no agreement could be reached. /s/ Nicole A. Rizzo Nicole A. Rizzo Dated: June 12, 2007 Boston, Massachusetts Respectfully submitted, F. HOFFMANN-LA ROCHE LTD, ROCHE DIAGNOSTICS GMBH, and HOFFMANN-LA ROCHE INC. By their attorneys, /s/ Nicole A. Rizzo Lee Carl Bromberg (BBO# 058480) Timothy M. Murphy (BBO# 551926) Julia Huston (BBO# 562160) Keith E. Toms (BBO# 663369) Nicole A. Rizzo (BBO# 663853) BROMBERG & SUNSTEIN LLP 125 Summer Street Boston, MA 02110 Tel. (617) 443-9292 nrizzo@bromsun.com 2 Case 1:05-cv-12237-WGY Document 490 Filed 06/12/2007 Page 3 of 3 Leora Ben-Ami (pro hac vice) Patricia A. Carson (pro hac vice) Thomas F. Fleming (pro hac vice) Howard S. Suh (pro hac vice) Christopher T. Jagoe (pro hac vice) KAYE SCHOLER LLP 425 Park Avenue New York, New York 10022 Tel. (212) 836-8000 CERTIFICATE OF SERVICE I hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non-registered participants on the above date. /s/ Nicole A. Rizzo Nicole A. Rizzo 03099/00501 681184.1 3

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.


Why Is My Information Online?